<DOC>
	<DOCNO>NCT01226693</DOCNO>
	<brief_summary>There difference rate extent absorption material spar tablet ( MST ) , Phase2b/3 formulation ( P2b/3 ) sodium lauryl sulphate ( SLS ) p2b/3 formulation without SLS .</brief_summary>
	<brief_title>A Study In Healthy Volunteers To Assess The Safety , Tolerability , And Relative Oral Bioavailability Of Three Formulations Of PH-797804</brief_title>
	<detailed_description />
	<criteria>Healthy male female subject nonchildbearing potential age 21 55 . No evidence active latent TB . An informed consent document sign date subject . Evidence , include abnormal clinical laboratory parameter , eg , liver enzyme elevation , history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) active GI disease ( include relevant surgery ) . Any current clinically significant skin lesion describe Common Terminology Criteria Adverse Events Dermatology ( CTCAE ) Version 3 . A clinically significant skin lesion define Grade 1 ( mild ) rash pruritus , Grade 2 ( moderate ) lesion ( see Short Name description CTCAE specific description lesion ) . Use prescription nonprescription drug , vitamin dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>single dose bioequivalence study</keyword>
	<keyword>balanced incomplete block design</keyword>
	<keyword>PH-797804</keyword>
	<keyword>P38 kinase inhibitor</keyword>
</DOC>